Pharma and Irish inversions: Increasing your share price

May 31, 2014

A spate of recent examples indicates that inversion transactions are as popular as they have ever been, with Pfizer’s attempted deal with AstraZeneca highlighting that companies in the pharmaceuticals industry are increasingly using the inversion option. William Fry Tax Advisors, the Irish member firm of Taxand, look at why this is, and analyse why Ireland is proving to be the location of choice for newly-formed companies post-inversion.

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login

Topics

more across site & bottom lb ros

More from across our site

Direct Tax

Co-sourcing in tax: a growing trend with pillar two

In-house teams who want a balance of internal control and external expertise for pillar two should seriously consider co-sourcing models, Russell Gammon of Tax Systems argues

Russell Gammon, January 22, 2025

Direct Tax

Trump: OECD’s pillar two ‘no force or effect’ in US

The OECD has vowed to continue working with the US despite the president effectively pulling the country out of the organisation’s global minimum tax deal

Sam Sholli, January 21, 2025

Direct Tax

Exploring the tax classification of non-Dutch entities in 2025

Norton Rose Fulbright highlights a Brazilian investment fund as a practical example of how new Dutch tax rules will require significant attention from foreign companies

Bart Le Blanc , January 20, 2025

Direct Tax